
Reflexões sobre a nova era de tratamento da obesidade e o papel do estilo de vida e exercício físico, baseado nos recentes estudos publicados abaixo.Referências
MOIZ, Areesha et al. Weight maintenance after discontinuation of GLP-1 therapies. eClinicalMedicine,v. 96, art. 103992, 2026. DOI: https://doi.org/10.1016/j.eclinm.2026.103992.
RUIZ, Jonatan R.; CIUDIN, Andreea; BUTRAGUEÑO, Javier.Strengthening the metabolic alliance: exercise as an essential partner ofobesity pharmacotherapy. Nature Reviews Endocrinology, 2026. DOI: https://doi.org/10.1038/s41574-026-01276-3.
BUTRAGUEÑO, Javier; RUIZ, Jonatan R. Metabolicalliance: pharmacotherapy and exercise management of obesity. NatureReviews Endocrinology, v. 20, n. 9, p. 505–506, 2024. DOI: https://doi.org/10.1038/s41574-024-01006-7.
SWIFT, Damon L. et al. Role of Physical Activity inObesity Treatment and Cardiometabolic Health: A Scientific Statement From theAmerican Heart Association. Circulation,v. 154, p. e1–e16, 2026. DOI: https://doi.org/10.1161/CIR.0000000000001441.
LIEBERMAN, Daniel E.; ASHEM, Alan H.; HEYMSFIELD,Steven B. The Conundrum of Exercise for Weight Management in the GLP-1Receptor Agonist Era. JAMA, v. 334, n. 1, 2025. DOI:https://doi.org/10.1001/jama.2025.8689.
VAN DER SCHOOT, J. M. et al. Weight regain aftercessation of medication for weight management: systematic review andmeta-analysis. BMC Medicine,v. 23, art. 319, 2025. DOI: https://doi.org/10.1186/s12916-025-04194-8